130 related articles for article (PubMed ID: 3186923)
1. Preclinical studies of porfiromycin as an adjunct to radiotherapy.
Rockwell S; Keyes SR; Sartorelli AC
Radiat Res; 1988 Oct; 116(1):100-13. PubMed ID: 3186923
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.
Rockwell S; Keyes SR; Sartorelli AC
Anticancer Res; 1989; 9(4):817-20. PubMed ID: 2479329
[TBL] [Abstract][Full Text] [Related]
3. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
[TBL] [Abstract][Full Text] [Related]
4. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1989 Jun; 49(12):3310-3. PubMed ID: 2470504
[TBL] [Abstract][Full Text] [Related]
5. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
Rockwell S
J Natl Cancer Inst; 1983 Oct; 71(4):765-71. PubMed ID: 6413743
[TBL] [Abstract][Full Text] [Related]
6. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1987 Nov; 47(21):5654-7. PubMed ID: 3664473
[TBL] [Abstract][Full Text] [Related]
7. Porfiromycin as an adjunct to radiotherapy in young and old mice.
Rockwell S; Hughes CS; Keyes SR; Sartorelli AC; Kennedy KA
Exp Gerontol; 1993; 28(3):281-93. PubMed ID: 8344398
[TBL] [Abstract][Full Text] [Related]
8. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.
Rockwell S; Keyes SR; Loomis R; Kelley M; Vyas DM; Wong H; Doyle TW; Sartorelli AC
Cancer Commun; 1991 Jun; 3(6):191-8. PubMed ID: 2049227
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
Fracasso PM; Sartorelli AC
Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1985 Jan; 45(1):213-6. PubMed ID: 2578093
[TBL] [Abstract][Full Text] [Related]
11. Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
Rockwell S; Kelley M
Radiother Oncol; 1996 Apr; 39(1):65-71. PubMed ID: 8735495
[TBL] [Abstract][Full Text] [Related]
12. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
Rockwell S; Kelley M
Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166
[TBL] [Abstract][Full Text] [Related]
13. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.
Haffty BG; Wilson LD; Son YH; Cho EI; Papac RJ; Fischer DB; Rockwell S; Sartorelli AC; Ross DA; Sasaki CT; Fischer JJ
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):119-28. PubMed ID: 15629602
[TBL] [Abstract][Full Text] [Related]
15. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
Pritsos CA; Keyes SR; Sartorelli AC
Cancer Biochem Biophys; 1989 Oct; 10(4):289-98. PubMed ID: 2559790
[TBL] [Abstract][Full Text] [Related]
16. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
Keyes SR; Heimbrook DC; Fracasso PM; Rockwell S; Sligar SG; Sartorelli AC
Adv Enzyme Regul; 1985; 23():291-307. PubMed ID: 3934922
[TBL] [Abstract][Full Text] [Related]
18. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio.
Rockwell S; Nierenburg M; Irvin CG
Cancer Treat Rep; 1987 Oct; 71(10):927-34. PubMed ID: 3652056
[TBL] [Abstract][Full Text] [Related]
19. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
[TBL] [Abstract][Full Text] [Related]
20. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics.
Pritsos CA; Sartorelli AC
Cancer Res; 1986 Jul; 46(7):3528-32. PubMed ID: 3011250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
